Cancer patients and COVID-19: Mortality, serious complications, biomarkers, and ways forward

Gupta, Kush; Gandhi, Shipra; Mebane, Alexander; Singh, Angelica; Vishnuvardhan, Nivetha; Patel, Eshan U.

doi:10.1016/j.ctarc.2020.100285

Cited by 28 publications

(18 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The initial governmental decisions had a strong impact on the healthcare system, as the focus shifted from usual practice to increasing capacities for intensive care, representing a shift from patient‐centered care to a more public health‐oriented approach. As cancer patients seem to be more vulnerable to the SARS‐CoV‐2 virus, 1,2 actions were undertaken that aimed at maintaining treatment and care while simultaneously protecting patients, and healthcare providers, from being infected with the new coronavirus. These included adaptation of treatment regimens and rescheduling of elective out‐patient visits 3–5 …”

Section: Crisis… and Adaptationmentioning

confidence: 99%

Psychooncological care for patients with cancer during 12 months of the Covid‐19 pandemic: Views and experiences of senior psychooncologists at German Comprehensive Cancer Centers

et al. 2021

View full text Add to dashboard Cite

Key points A monthly videoconference was maintained over 1 year, allowing senior psychooncologists from German Comprehensive Cancer Centers to discuss the implications of the Covid‐19 pandemic for psychooncological care. In the early phase of the pandemic, a widespread disruption of psychooncological services was noted. Rapidly developed adaptations of regular services worked well and sometimes brought about unexpected, creative solutions. In March 2021, the high numbers of infections, the occurrence of new variants of the coronavirus, and the slow progress in vaccination raise fears about new disruptions and restrictions in service provision. In coping with the pandemic, many therapists have felt like many cancer patients do feel in the process of coping with cancer, and this might help to better understand our patients.

show abstract

Section: Crisis… and Adaptationmentioning

confidence: 99%

Psychooncological care for patients with cancer during 12 months of the Covid‐19 pandemic: Views and experiences of senior psychooncologists at German Comprehensive Cancer Centers

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Particular populations, such as the elderly, pregnant women, and those with chronic diseases, are more susceptible to SARS-CoV-2 infection’s adverse effects [ 12 , 13 , 14 , 15 ]. According to current data, patients with malignancies are at a higher risk for life-threatening infections [ 16 , 17 ]. The presence of active cancer such as melanoma and chemotherapy for melanoma may reduce physical capacity and trigger immunosuppression, hence escalating the requirement for hospitalization and hospital visits and admissions [ 18 ].…”

Section: Introductionmentioning

confidence: 99%

The Impact of SARS-CoV-2 Pandemic on Patients with Malignant Melanoma at a Romanian Academic Center: A Four-Year Retrospective Analysis

Aabed

Bloanca

Crăiniceanu

et al. 2022

IJERPH

View full text Add to dashboard Cite

Considering cancer patients may be at an increased risk of severe COVID-19 disease, their oncologic treatment cannot be delayed without risking their oncologic outcomes. Considering this, a comprehensive evaluation is required for the management of malignant diseases such as melanoma. The current study aimed to assess the impact of the COVID-19 pandemic on the delivery of cancer care services for patients diagnosed with malignant melanoma in Romania; to document the difference in patients’ addressability and melanoma staging between the pandemic and pre-pandemic periods; as well as to determine the risk factors responsible for disease progression during the pandemic. We developed a retrospective analysis using a monocentric hospital database to compare the final 24 months of the pre-pandemic era to the first 24 months of the COVID-19 pandemic. All outpatients and inpatients with a diagnosis of malignant melanoma were screened during the study period and included in the analysis if matching the inclusion criteria. A total of 301 patients were included in the study, with 163 cases identified in the 24 months before the COVID-19 pandemic and 138 patients during the first 24 months of the pandemic. It was observed during the first two lockdown periods from March to May 2020, and, respectively, from October to December 2020, that significantly fewer patients with malignant melanoma presented for specialized medical care, while there was a statistically significantly lower proportion of outpatients due to COVID-19 restrictions (18.1% vs. 42.9%). The average Breslow depth was 1.1 mm before the pandemic, compared with 1.8 mm during the pandemic (p-value < 0.001). Third-stage patients were the most prevalent during both study periods, although with a statistically significant difference during the pandemic, with an increase from 90 (55.2%) patients to 94 (68.1%) (p-value < 0.001). The significant risk factors for disease progression were advanced AJCC stage (HR = 3.48), high Breslow index (HR = 3.19), postponed treatment (HR = 2.46), missed appointments (HR = 2.31), anemia at presentation (HR = 1.60), and patient’s age (HR = 1.57). After the pandemic limitations are brought to an end, a broad skin-cancer-screening campaign is warranted to detect the missed cases during COVID-19.

show abstract

“…Treatments are delayed, pain medications are lacking, and some cancer-related clinical trials are stopped. The ability to undergo surgeries and treatments has also been drastically reduced [ 27 , 28 , 29 ]. It seems justified to continue searching for potential drugs for diseases that kill most people.…”

Section: Introductionmentioning

confidence: 99%

Characterization of Metal-Bound Benzimidazole Derivatives, Effects on Tumor Cells of Lung Cancer

et al. 2021

View full text Add to dashboard Cite

Four new ligands and four new copper (II) coordination compounds were prepared and characterized by chemical, elemental analysis, cytotoxicity, and FTIR spectroscopy (Fourier transform infrared spectroscopy). The nature of metal–ligand coordination was investigated. The thermal properties of complexes in the solid state were studied using TG-MS techniques (thermogravimetric analysis coupled with mass spectrometry) under dynamic flowing air atmosphere to analyze the principal volatile thermal decomposition and fragmentation products that evolved during thermolysis. The intermediate and final solid thermolysis products were also determined. The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide) assay was used to evaluate active metabolic cells as an IC50 (half maximal inhibitory concentration). The relationship between antitumor activity and the position of nitrogen atoms in the organic ligand has been shown.

show abstract

Cancer patients and COVID-19: Mortality, serious complications, biomarkers, and ways forward

Cited by 28 publications

References 71 publications

Psychooncological care for patients with cancer during 12 months of the Covid‐19 pandemic: Views and experiences of senior psychooncologists at German Comprehensive Cancer Centers

Psychooncological care for patients with cancer during 12 months of the Covid‐19 pandemic: Views and experiences of senior psychooncologists at German Comprehensive Cancer Centers

The Impact of SARS-CoV-2 Pandemic on Patients with Malignant Melanoma at a Romanian Academic Center: A Four-Year Retrospective Analysis

Characterization of Metal-Bound Benzimidazole Derivatives, Effects on Tumor Cells of Lung Cancer

Contact Info

Product

Resources

About